Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB122 phase 2b trial in early Parkinson's disease
NL-OMON51537Phase 2Not yet recruiting
- Sponsor
- Biogen
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing BIIB122 with Placebo (2 arms). Primary endpoint: Time to confirmed worsening in MDS-UPDRS Parts II and III combined score. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
BIIB122
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON51537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51537.